The neutrophil-to-lymphocyte ratio in salivary gland cancers treated with pembrolizumab.

Rex H LeeAngeline TruongXin WuHyunseok KangAlain P AlgaziIvan H El-SayedJonathan R GeorgeChase M HeatonWilliam R RyanPatrick K HaKatherine C Wai

Published in: Head & neck (2023)

Higher pretreatment NLR was independently associated with inferior 6-month PFS and 2-year OS in pembrolizumab-treated R/M SGC patients.

Keyphrases